Home › Funds › Eagle Health Investments LP › BSX
Eagle Health Investments LP position in BSX
BOSTON SCIENTIFIC CORP · Health Care
Eagle Health Investments LP reported holding 459,114 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$20.0M, representing 3.61% of its reported portfolio and ranking #14 among its reported holdings. Eagle Health Investments LP has disclosed BSX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Eagle Health Investments LP's BSX position evolved
Eagle Health Investments LP first disclosed a stake in BSX in Q1 2026 at 293,152 shares (US$18.4M). The position peaked in Q3 2026 at 459,114 shares, worth US$20.0M. Across 3 filings, Eagle Health Investments LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 459,114 shares valued at US$20.0M — an increase of 89,950 shares quarter over quarter.. Notable position changes include a 26% increase in Q2 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 293.15K | $18.40M | New |
| Q2 2026 | 369.16K | $15.76M | Add |
| Q3 2026 | 459.11K | $20.04M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 18 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), Arrowstreet Capital (US$1.24B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- PRIMECAP MANAGEMENT CO/CA/ 58.62M sh · $2.56B · Q3 2026
- MFS Investment Management 43.05M sh · $2.29B · Q3 2026
- Arrowstreet Capital 28.47M sh · $1.24B · Q3 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
More on Eagle Health Investments LP
FAQ
How long has Eagle Health Investments LP held BSX?
Eagle Health Investments LP has disclosed BSX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Eagle Health Investments LP's current position in BSX?
As of Q3 2026, Eagle Health Investments LP holds 459.11K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $20.04M, representing 3.61% of its reported portfolio and ranking #14.
Has Eagle Health Investments LP been buying or selling BSX?
In the latest 13F filing (Q3 2026), Eagle Health Investments LP increased its position in BSX. The position peaked in Q3 2026 at 459.11K shares.
Which other funds hold BSX?
Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, Arrowstreet Capital, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.